| Terminal complement inhibitor eculizumab in atypical hemolytic–uremic syndrome CM Legendre, C Licht, P Muus, LA Greenbaum, S Babu, C Bedrosian, ... New England Journal of Medicine 368 (23), 2169-2181, 2013 | 1609 | 2013 |
| An international consensus approach to the management of atypical hemolytic uremic syndrome in children C Loirat, F Fakhouri, G Ariceta, N Besbas, M Bitzan, A Bjerre, R Coppo, ... Pediatric nephrology 31, 15-39, 2016 | 661 | 2016 |
| Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes”(KDIGO) Controversies Conference THJ Goodship, HT Cook, F Fakhouri, FC Fervenza, V Frémeaux-Bacchi, ... Kidney international 91 (3), 539-551, 2017 | 649 | 2017 |
| Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test AC Lionel, G Costain, N Monfared, S Walker, MS Reuter, SM Hosseini, ... Genetics in Medicine 20 (4), 435-443, 2018 | 517 | 2018 |
| Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome G Ariceta, N Besbas, S Johnson, D Karpman, D Landau, C Licht, C Loirat, ... Pediatric nephrology 24, 687-696, 2009 | 486 | 2009 |
| Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies C Licht, LA Greenbaum, P Muus, S Babu, CL Bedrosian, DJ Cohen, ... Kidney international 87 (5), 1061-1073, 2015 | 448 | 2015 |
| Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency M Józsi, C Licht, S Strobel, SLH Zipfel, H Richter, S Heinen, PF Zipfel, ... Blood, The Journal of the American Society of Hematology 111 (3), 1512-1514, 2008 | 390 | 2008 |
| Deletion of Complement Factor H–Related Genes CFHR1 and CFHR3 Is Associated with Atypical Hemolytic Uremic Syndrome PF Zipfel, M Edey, S Heinen, M Józsi, H Richter, J Misselwitz, B Hoppe, ... PLoS genetics 3 (3), e41, 2007 | 384 | 2007 |
| Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy O Gross, C Licht, HJ Anders, B Hoppe, B Beck, B Tönshoff, B Höcker, ... Kidney international 81 (5), 494-501, 2012 | 373 | 2012 |
| New approaches to the treatment of dense deposit disease RJH Smith, J Alexander, PN Barlow, M Botto, TL Cassavant, HT Cook, ... Journal of the American Society of Nephrology 18 (9), 2447-2456, 2007 | 331 | 2007 |
| Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome LA Greenbaum, M Fila, G Ardissino, SI Al-Akash, J Evans, P Henning, ... Kidney international 89 (3), 701-711, 2016 | 285 | 2016 |
| Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy S Jodele, C Licht, J Goebel, BP Dixon, K Zhang, TA Sivakumaran, ... Blood, The Journal of the American Society of Hematology 122 (12), 2003-2007, 2013 | 264 | 2013 |
| Eculizumab therapy in children with severe hematopoietic stem cell transplantation–associated thrombotic microangiopathy S Jodele, T Fukuda, A Vinks, K Mizuno, BL Laskin, J Goebel, BP Dixon, ... Biology of Blood and Marrow Transplantation 20 (4), 518-525, 2014 | 250 | 2014 |
| Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II) C Licht, S Heinen, M Jozsi, I Löschmann, RE Saunders, SJ Perkins, ... Kidney international 70 (1), 42-50, 2006 | 247 | 2006 |
| aHUS caused by complement dysregulation: new therapies on the horizon AM Waters, C Licht Pediatric Nephrology 26, 41-57, 2011 | 197 | 2011 |
| Identification of a rare coding variant in complement 3 associated with age-related macular degeneration X Zhan, DE Larson, C Wang, DC Koboldt, YV Sergeev, RS Fulton, ... Nature genetics 45 (11), 1375-1379, 2013 | 189 | 2013 |
| Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative CE Kashtan, J Ding, M Gregory, O Gross, L Heidet, B Knebelmann, ... Pediatric nephrology 28, 5-11, 2013 | 174 | 2013 |
| Outrageous prices of orphan drugs: a call for collaboration L Luzzatto, HI Hyry, A Schieppati, E Costa, S Simoens, F Schaefer, ... The Lancet 392 (10149), 791-794, 2018 | 168 | 2018 |
| Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches M Riedl, F Fakhouri, M Le Quintrec, DG Noone, TC Jungraithmayr, ... Seminars in thrombosis and hemostasis 40 (04), 444-464, 2014 | 161 | 2014 |
| Factor H and atypical hemolytic uremic syndrome: mutations in the C-terminus cause structural changes and defective recognition functions M Józsi, S Heinen, A Hartmann, CW Ostrowicz, S Hälbich, H Richter, ... Journal of the American Society of Nephrology 17 (1), 170-177, 2006 | 159 | 2006 |
